CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Niagen Bioscience Q3 sales fall, miss estimates

By Reuters News


Overview

  • U.S. healthy aging supplement maker's Q3 net sales fell and missed analyst expectations

  • Company posted a net loss for Q3

  • Adjusted EBITDA positive for the quarter


Outlook

  • Company expects 2026 direct website revenues to grow 15% to 20% year-over-year

  • Company sees overall e-commerce revenue up about 5% year-over-year in 2026

  • Ingredient business expected to decline in 2026 due to lower volume from key partners


Result Drivers

  • E-COMMERCE GROWTH - Direct-to-consumer website sales grew 13% year-over-year

  • NEW PRODUCT LAUNCHES - Co introduced Niagen Plus At-Home Injection Kit and Niagen NanoCloud topical product during the qtr

  • RETAIL EXPANSION - Tru Niagen launched on Walmart.com and in nearly 300 GNC and Sam’s Club locations across 44 states


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Miss

$27.19 mln

$32.06 mln (6 Analysts)

Q3 Net Loss

$1.17 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Niagen Bioscience Inc is $10.00, about 323.7% above its November 3 closing price of $2.36

  • The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 12 three months ago


Reuters Recommended Reads

  • Nov 3 - USANA Health Sciences Q3 sales fall 4%, cuts full year outlook

  • Nov 3 - Chegg Q3 revenue falls as legacy business declines


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.